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Clinical vignette 
A 40 year-old female with no significant 
past medical history had a 3-day history of 
runny nose, headache, cough and post-nasal 
drip. Her physical exam showed 
erythematous pharyngeal wall but it was 
otherwise unremarkable. Her primary care 
provider prescribed amoxicillin-clavulanic 
acid for 7 days. She finished the antibiotic 
course, her symptoms gradually improved 
but she developed watery diarrhea up to 5 
times per day. Her vital signs, blood cell 
counts, renal function and chemistries were 
normal. Her Clostridium difficile test 
returned positive. What treatment would you 
recommend for this patient? 
a. Oral metronidazole 
b. Oral vancomycin 
c. Intravenous metronidazole 
d. Rifaximin 
 
There are two teaching points in this case: 1) 
this patient should not have gotten antibiotic 
therapy for what was most probably a viral 
illness; 2) even for non-severe cases of 
Clostridium difficile infection (CDI) such as 
this, the recommended treatment now is oral 
vancomycin. Oral metronidazole should be 
used only in non-severe cases if oral 
vancomycin or fidaxomicin cannot be 
obtained. Intravenous metronidazole is only 
used as adjunctive therapy in fulminant CDI. 
Rifaximin is used as a chaser following 
completion of oral vancomycin in recurrent 
CDI.  
Key recommendations from the Clinical 
Practice Guidelines for Clostridium 
difficile Infection in Adults and Children: 
2017 Update by the Infectious Diseases 
Society of America (IDSA) and Society 
for Healthcare Epidemiology of America 
(SHEA) 
 
1. Nucleic acid amplification test (NAAT) 
alone is sufficient for testing if there is 
an institutional policy to not submit stool 
specimens on patients receiving 
laxatives and to submit stool specimens 
only from patients with unexplained, 
new onset diarrhea (3 or more stools in 
24 h). Otherwise, use stool toxin test 
within a multiple step algorithm. 
2. Do not repeat testing during the same 
episode of diarrhea and do not test 
formed stools (asymptomatic patients). 
3. After resolution of diarrhea, contact 
precautions should be continued for at 
least 48 hours.  
4. Use soap and water or an alcohol-based 
product for hand hygiene before and 
after contact of a patient with CDI. 
5. Attempt to reduce the frequency, 
duration and number of antibiotics 
prescribed. Specifically, restrict the use 
of clindamycin, fluoroquinolones and 
cephalosporins. Antibiotic stewardship 
programs should exist in every hospital. 
6. There is insufficient evidence to 
recommend discontinuation of proton 
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pump inhibitors or use of probiotics as 
measures to prevent CDI. 
7. Discontinue therapy with the inciting 
antibiotic as soon as possible, as this 
may influence the risk of CDI 
recurrence.  
8. For a first episode of CDI, severe or 
non-severe, use vancomycin or 
fidaxomicin. Metronidazole should only 
be used when access to vancomycin or 
fidaxomicin is limited, and only in non-
severe cases.   
9. For fulminant CDI (megacolon, 
hypotension or shock, ileus), oral 
vancomycin 500 mg 4 times a day is 
recommended. If ileus is present, rectal 
vancomycin should be added. 
Intravenous metronidazole 500 mg every 
8 hours should be administered together 
with oral or rectal vancomycin, 
particularly if ileus is present.  
10. Treat a first recurrence of CDI with oral 
vancomycin pulse and taper or a 10-day 
course of fidaxomicin rather than a 
second standard 10-day course of 
vancomycin, which could be considered 
if the primary episode was treated with 
metronidazole.  
11. For patients with > 1 recurrence, the 
options are: vancomycin in a tapered and 
pulsed regimen, vancomycin for 10 days 
followed by rifaximin for 20 days, 
fidaxomicin, or fecal microbiota 
transplantation.  
12. There is insufficient evidence to 
recommend extending or restarting anti-
CDI treatment for patients who require 
antibiotics for other infections.  
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